There are several treatment methods for lymphoma, which are currently chosen internationally according to NCCN guidelines, taking into account the disease (pathology and stage) and economic conditions: i. Radiation therapy Radiation therapy for Hodgkin’s disease (HD) has achieved remarkable success. It is more effective, but it is better to apply linear gas pedal. There are two methods of irradiating HD ⅠA to ⅡB with high-energy rays over a large area: expanded and whole-body lymph node irradiation. In addition to the accumulated lymph nodes and tumor tissues, the expanded irradiation must also include the nearby lymph node areas that may be invaded, for example, the lesion is cloaked in a septum. For example, the lesion is irradiated in a cloak style on the septum and in an inverted “Y” style under the septum. The cloak irradiation site includes both sides from the mastoid end of the clavicle up and down, the axilla, the pulmonary hilum, the mediastinum and the lymph nodes in the septum; the head of the humerus, the larynx and the lungs should be protected from irradiation. Inverted “Y” irradiation includes lymph nodes from the subdiaphragmatic lymph nodes to the para-aortic, pelvic and inguinal lymph nodes, as well as the splenic area. The dose is 30-40Gy and the course of treatment is 3-4 weeks. The whole body lymph nodes are irradiated, i.e., the diaphragm is irradiated in a cloak and the subdiaphragm is irradiated in an inverted “Y” pattern. Non-Hodgkin’s lymphoma HNL is also sensitive to radiotherapy but has a high recurrence rate. Since the pathway of spread is not along the lymphatic area, the importance of large irregular irradiated fields in the cloak and inverted “Y” pattern is much less than that of HD. Currently, only the clinical stage I and II of the low malignancy group and the pathological stage I of the moderate malignancy group can be irradiated with expanded fields alone or with local irradiation of the involved fields alone. There is no unanimous opinion on whether chemotherapy is used after radiotherapy. Stage III and IV are mostly treated with Wallace-based, local radiotherapy as palliative treatment if necessary. Second, chemotherapy Very most of the use of combined chemotherapy, to strive for the first treatment that obtains complete remission, to create favorable conditions for long-term survival without and. (i) Hodgkin’s disease Since the MOPP/ABVD program, the prognosis of advanced HD has greatly improved. MOPP is less effective in patients with significant systemic symptoms; bone marrow involvement; history of repeated chemotherapy; and lymphatic depletion or nodular sclerosis with mediastinal involvement. For MOPP is ineffective, ABVD can be used, and some of them can be in remission, and MOPP and ABVD are also used alternately. (B) Non-Hodgkin’s lymphoma Chemotherapy efficacy is determined by pathological tissue type, while clinical stage is less important than HD. combined chemotherapy regimens are selected according to the degree of malignancy of pathological classification: 1. Low malignancy group This group can be relapse-free and survive up to 10 years after radiotherapy in stage I and II; however, in stage III and IV, both radiotherapy and chemotherapy fail to achieve healing. Although the effect of strong chemotherapy is still good, the recurrence rate is high. Therefore, it is advocated that patients in this group should postpone chemotherapy treatment as much as possible and observe closely on a regular basis. 2.Moderate malignancy group All types of this group, once the diagnosis is clear and the clinical stage is III, IV accumulation and a wide range of II stage, should be immediately given COP, CHOP, m-BACOD, ProMACE-MOPP, COP-BLAM-III and MACOP-B chemotherapy, if the patient pathology has CD20 (+), can also be combined with Merova treatment. 3, highly malignant group All should be given intense combination chemotherapy. Selected lymphocytic type and Burkitt lymphoma progresses faster ah, if not treated, death within a few weeks or months. For highly malignant group with second or third generation combination chemotherapy is worse. Bone marrow transplantation For patients under 40 years old who can tolerate high-dose chemotherapy, whole lymph node radiotherapy and high-dose combination chemotherapy combined with allogeneic or own bone marrow transplantation can be considered to achieve longer-term remission and disease-free survival. At present, domestic and foreign research on auto-bone marrow transplantation has achieved encouraging results in diffuse and progressive lymphoma, but the problem of auto-bone marrow transplantation remains to be solved in terms of auto-bone marrow decontamination in vitro. Surgical treatment is limited to biopsy only; in case of combined hypersplenism, splenectomy is indicated to improve the blood picture and create favorable conditions for later chemotherapy. Interferon has growth regulating and anti-proliferative effects. For myxoid granuloma, follicular small cleaved cell predominantly and diffuse large cell type have partial remission effect. The method of application and exact efficacy are still being explored in practice.